A multicenter prospective observational study investigating TARlatamab Guidance for Efficacy and Toxicity in patients with extensive disease small cell lung cancer

A multicenter prospective observational study investigating TARlatamab Guidance for Efficacy and Toxicity in patients with extensive disease small cell lung cancer - TARGET study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057729

Enrollment

Registered

2025-04-28

Start date

2025-04-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extensive disease small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients determined to have extensive disease small cell lung cancer 2. Patients with more than 2 treatment lines 3. Patients scheduled to receive tarlatamab

Exclusion criteria

Exclusion criteria: nothing in particular

Design outcomes

Primary

Measure	Time frame
Anti-tumor effects and incidence of adverse events by peripheral blood mono-nuclear cell subset frequency in patients treated with tarlatamab	—

Countries

Japan

Contacts

Public ContactKinnosuke Matsumoto

Graduate School of Medicine, Osaka University Department of Respiratory Medicine and Clinical Immunology

m.kinnosuke@gmail.com06-6879-3831

Outcome results